Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 6, Number 6—December 2000

Perspective

Evidence Against Rapid Emergence of Praziquantel Resistance in Schistosoma haematobium, Kenya

Charles H. King*, Eric M. Muchiri†, and John H. Ouma†
Author affiliations: *Case Western Reserve University School of Medicine and University Hospitals of Cleveland, Cleveland, Ohio, USA; †Ministry of Health, Nairobi, Kenya

Main Article

Figure 3

Extra doses needed to cure Schistosoma haematobium infection in 1984-entry cohort children who were not cured with a first dose of praziquantel (initial nonresponse, N=123, top bar) compared with doses needed to cure children reinfected after successful praziquantel treatment (reinfected post-cure, N= 36, bottom bar). The filled areas in each bar indicate the percentage of each group requiring one (solid), two (hatched), or three (shaded) more doses of praziquantel to become egg negative. No sig

Figure 3. Extra doses needed to cure Schistosoma haematobium infection in 1984-entry cohort children who were not cured with a first dose of praziquantel (initial nonresponse, N=123, top bar) compared with doses needed to cure children reinfected after successful praziquantel treatment (reinfected post-cure, N= 36, bottom bar). The filled areas in each bar indicate the percentage of each group requiring one (solid), two (hatched), or three (shaded) more doses of praziquantel to become egg negative. No significant differences were observed between the two groups in age, sex, or cure rates.

Main Article

TOP